-- 加拿大皇家銀行資本市場預計，加拿大央行下週將保持「穩健」的政策態勢，鑑於過去一個月經濟數據趨於穩定，央行的表態「可能比3月的會議更加鷹派」。 加拿大皇家銀行在周五發布的例行「加幣每週簡訊」中表示，其仍認為加拿大央行將在2026年維持利率不變，並在2027年升息。升息提前至2026年下半年的風險高於今年降息的可能性（「但這是一個緩慢的過程」）。該行也補充道，年度中性利率評估預計不會改變2.25%至3.25%的區間。 關於加美利差，加拿大皇家銀行指出，伊朗衝突帶來的不確定性導致加幣利率表現優於美國利率，加美10年期公債利差從上週五的-79個基點升至-84個基點。 從技術面來看，加拿大皇家銀行(RBC)的喬治·戴維斯(George Davis)表示，如果加拿大10年期國債收益率的日線收盤價跌破3.44%的阻力位，則近期的下跌趨勢將得以延續，並可能進一步下探至3.39%的近期低點以及3月18日的低點3.36%。初步支撐位在3.50%和3.55%，若要打破看漲債券的預期，則需要回升至3.62%以上。 在加拿大央行會議召開前，RBC指出，聯邦政府週二發布的財政更新報告「更有可能顯示財政狀況改善」。 RBC預計，在執政的自由黨本月稍早贏得議會多數席次後，財政支出計畫不會發生重大變化。 RBC表示，風險偏好在於剛結束的2025-2026財年和目前的2026-2027財年，赤字都會降低，財政數據也會有所改善。 RBC補充道，除非美加利率差收窄速度超過預期，或市場對美國資產賦予更高的風險溢價，否則美元/加幣短期內可能仍將維持區間震盪。
Related Articles
Treasury
Scotiabank Previews This Week's February and Preliminary March GDP for Canada
Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.
$$CXY
Australia
Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing
Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%
$VICR
Australia
BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says
BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%
$BMRN$FOLD